LinusBio vs Pliant Therapeutics
Side-by-side comparison of AI visibility scores, market position, and capabilities
LinusBio is a precision medicine company using AI-powered exposome sequencing of hair samples to detect environmental and genetic disease risk factors; focuses on early autism detection; spun out of MIT; raised $12.5M in Series A funding.
About
LinusBio is a precision medicine and diagnostics company founded by Manish Arora and headquartered in New York, with roots in research at the Icahn School of Medicine at Mount Sinai and MIT. The company has developed a proprietary technology platform called exposome sequencing — a method of analyzing biological samples, primarily hair, to reconstruct a detailed timeline of environmental exposures and biological changes over months or years. This approach enables early detection of disease risk factors by reading both genetic and environmental signals simultaneously.
Pliant Therapeutics is a clinical-stage biotech (Nasdaq: PLRX) developing integrin inhibitors for fibrotic diseases, with lead program bexotegrast in Phase 2b/3 trials for idiopathic pulmonary fibrosis.
About
Pliant Therapeutics develops small molecule integrin inhibitors targeting the pathological tissue scarring (fibrosis) that drives diseases including idiopathic pulmonary fibrosis (IPF), primary sclerosing cholangitis (PSC), and nonalcoholic steatohepatitis (NASH/MASH). Integrins are cell surface receptors that activate TGF-β, the master regulator of fibrosis — blocking specific integrin subtypes (αvβ6, αvβ1) can halt or reverse fibrosis progression without broadly suppressing immunity.
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.